SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03634059

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.

NCT03634059 NSCLC

1 Interventions

Name: Apatinib

Description: apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po

Type: Drug

apatinib


Primary Outcomes

Description: Baseline to measured date of progression or death from any cause

Measure: Progression free survival

Time: evaluated in two years since the treatment began

Secondary Outcomes

Description: Baseline to measured stable disease

Measure: Objective response rate

Time: tumor assessment every 8 weeks,up to two years

Description: Baseline to measured progressive disease

Measure: Disease control rate (DCR)

Time: tumor assessment every 8 weeks,up to two years

Description: Baseline to measured date of death from any cause

Measure: Overall survival (OS)

Time: the first day of treatment to death or last survival confirm date,up to two years

Description: throughout study

Measure: Adverse events

Time: evaluated in the two years since the treatment began according to the Common Terminology Criteria for Adverse Events Version 4.0

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 L858R

Inclusion Criteria: 1. Age:18 to 75 years old (man or female); 2. Pathologically diagnosed with non-squamous NSCLC; 3. Imageology diagnosed with locally advanced/metastatic or recurrent (stage ⅢB - IV); 4. Histologically or cytologic confirmed,harboring an activating EGFR mutation (19del or 21 L858R); 5. None previous chemotherapy or targeted therapy.(NOTE: --- L858R ---



HPO Nodes